Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.

被引：0
|
作者：
Ma, Shuxiang
He, Zhen
Wang, Lili
Wu, Yufeng
Yang, Sen
Chen, Haiyang
Wu, Yingxi
Mo, Yuqing
Liu, Yang
Wang, Qiming
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8516
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial
    Ma, Shuxiang
    He, Zhen
    Liu, Yang
    Wang, Lili
    Yang, Sen
    Wu, Yufeng
    Chen, Haiyang
    Wu, Yingxi
    Wang, Qiming
    [J]. ECLINICALMEDICINE, 2024, 70
  • [2] A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensivedisease small cell lung cancer
    Wang, Z.
    Han, X.
    Guo, J.
    Li, L.
    Huang, Y.
    Ma, L.
    Zhao, M.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
  • [3] Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial
    Han, Xiao
    Guo, Jun
    Li, Lingyu
    Huang, Yong
    Meng, Xue
    Wang, Linlin
    Zhu, Hui
    Meng, Xiangjiao
    Shao, Qian
    Li, Xing
    Zhang, Yan
    Wang, Jin
    Chen, Yanhua
    Zhang, Yingjie
    Chen, Yiru
    Zhu, Changbin
    Wang, Zhehai
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [4] A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer
    Wang, Z.
    Han, X.
    Guo, J.
    Li, L.
    Huang, Y.
    Ma, L.
    Zhao, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S710 - S710
  • [5] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Xuetian Gao
    Ling Peng
    Li Zhang
    Kai Huang
    Cuihua Yi
    Bei Li
    Xue Meng
    Jisheng Li
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2661 - 2671
  • [6] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Gao, Xuetian
    Peng, Ling
    Zhang, Li
    Huang, Kai
    Yi, Cuihua
    Li, Bei
    Meng, Xue
    Li, Jisheng
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2661 - 2671
  • [7] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Gong, Jinhong
    Wan, Qian
    Shang, Jingjing
    Qian, Xiaodan
    Su, Dan
    Sun, Zhiqiang
    Liu, Guangjun
    [J]. ADVANCES IN THERAPY, 2021, 38 (10) : 5116 - 5126
  • [8] Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
    Krainhoefer, Josephine
    Walther, Mario
    Steinert, Matthias
    Reissig, Angelika
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [9] Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
    Jinhong Gong
    Qian Wan
    Jingjing Shang
    Xiaodan Qian
    Dan Su
    Zhiqiang Sun
    Guangjun Liu
    [J]. Advances in Therapy, 2021, 38 : 5116 - 5126
  • [10] Combining sintilimab with anlotinib as second-line or later therapy in patients with extensive-disease small cell lung cancer: A prospective, single-arm, phase II trial
    Shuxiang, M.
    Zhen, H.
    Lili, W.
    Yufeng, W.
    Sen, Y.
    Haiyang, C.
    Yingxi, W.
    Wang, Q.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1402 - S1402
12345